Skip to main content
Download PDF

Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study

BMC Infectious Diseases volume 22, Article number: 759 (2022) Cite this article

Abstract

Respiratory syncytial virus (RSV) infection is a major cause of morbidity in children. However, its disease burden remains poorly understood, particularly outside of the hospital setting. Our study aimed to estimate the burden of medically attended acute lower respiratory infection (ALRI) cases potentially related to RSV in Spanish children. Longitudinal data from September 2017 to June 2018 of 51,292 children aged < 5 years old from the National Healthcare System (NHS) of two Spanish regions were used. Three case definitions were considered: (a) RSV-specific; (b) RSV-specific and unspecified acute bronchiolitis (RSV-specific and Bronchiolitis), and; (c) RSV-specific and unspecified ALRI (RSV-specific and ALRI). A total of 3460 medically attended ALRI cases potentially due to RSV were identified, of which 257 (7.4%), 164 (4.7%), and 3039 (87.8%) coded with RSV-specific, unspecific bronchiolitis, and unspecific ALRI codes, respectively. Medically attended RSV-specific and ALRI cases per 1000 children was 134.4 in the first year of life, 119.4 in the second, and 35.3 between 2 and 5 years old. Most cases were observed in otherwise healthy children (93.1%). Mean direct healthcare cost per medically attended RSV-specific and ALRI case was €1753 in the first year of life, €896 in the second, and €683 between 2 and 5 years old. Hospitalization was the main driver of these costs, accounting for 55.6%, 38.0% and 33.4%, in each respective age group. In RSV-specific cases, mean direct healthcare cost per medically attended case was higher, mostly due to hospitalization: €3362 in the first year of life (72.9% from hospitalizations), €3252 in the second (72.1%), and €3514 between 2 and 5 years old (74.2%). These findings suggest that hospitalization data alone will underestimate the RSV infections requiring medical care, as will relying only on RSV-specific codes. RSV testing and codification must be improved and preventive solutions adopted, to protect all infants, particularly during the first year of life.

Peer Review reports

Background

Respiratory syncytial virus (RSV) infection is a global public health challenge and a major cause of mortality and morbidity in children, specially infants [1,2,3]. Clinical manifestations associated with RSV infection that usually drive demand of healthcare resources in children are bronchiolitis, pneumonia and other acute lower respiratory infections [4]. Young age and being born preterm or having medical conditions such as congenital heart disease, bronchopulmonary dysplasia, malformations, neuromuscular diseases, or immunological disorders are known risk factors for severe complications [4, 5], although most cases are observed in otherwise healthy children born at term [6,7,8]. The RSV Evidence-a Geographical Archive of the Literature (REGAL) series estimated that, in the Western countries, RSV was associated with 12–63% of all acute respiratory infections (ARIs) and 19–81% of all viral ARIs leading to hospitalizations in children [1].

The near advent of RSV preventive tools has increased the priority on understanding the real-world burden caused by this infectious agent, in order to support the assessment of new preventive options, once they become available [9]. However, several knowledge gaps still exist and substantial variation is found in reported incidence rates across studies [4]. On one hand, studies often include only RSV-specific and/or acute bronchiolitis diagnosis codes—or RSV confirmed cases when laboratory data is available—approaches which are expected to widely underestimate the number of RSV cases, due to lack of systematic testing and coding [10,11,12]. On the other hand, most studies focus on hospitalizations, leaving outside substantial direct healthcare burden from outpatient visits [7, 13,14,15]. In United States, a study found the incidence of RSV cases in the outpatient setting to be over thirty times higher than the incidence of hospitalizations [7]. In Spain, Quiles et al. reported that, in Valencia, nearly 90% of the bronchiolitis cases in children < 2 years were managed in outpatient settings [13].

The objective of this study was to estimate the incidence and burden (clinical and economic) of medically attended acute lower respiratory infection (ALRI) cases potentially related to RSV in Spanish children aged < 5 years old in two Spanish regions and assessing the impact of using distinct RSV definitions.

Methods

Study design

The Burden of Acute Respiratory Infections (BARI) study is a multidimensional real-world evidence study assessing the clinical and economic burden of acute respiratory infections (influenza and respiratory syncytial virus) in Spain. We are reporting here the results for a retrospective cost-of-illness analysis conducted using data from a longitudinal electronic medical records database from two Spanish regions to estimate the direct healthcare cost per medically attended potential RSV case in children aged < 5 years old during the epidemic season 2017/18, from the perspective of the Spanish National Health Service (NHS).

Database

This study used an IQVIA database including anonymized data extracted from the electronic medical records (EMR) of four Spanish regions, available between January 2017 and December 2018. Due to confidentiality agreements in place, the specific regions included in the database cannot be disclosed. The information collected in the database is provided by the regions themselves.

This database includes patients’ characteristics (age, gender), all their visits to distinct NHS healthcare providers and their diagnosis leading to the healthcare visit—using the International Classification of Diseases 9th Revision (ICD-9-MC) and 10th Revision (ICD-10-ES) and International Classification for Primary Care (ICPC-2), depending on the region—as well as related comorbidities or other significant diseases. It enables a traceability of resource consumption per patient across distinct healthcare settings, namely including information from primary care general practitioners and nurses activities, specialized care (outpatient’s consultations), visits to the emergency department, hospitalizations and retail pharmaceutical products prescribed by physicians. Information on acute and chronic diagnoses with date of diagnostic is available for every inhabitant, thus enabling the identification of individuals who had a potential RSV diagnosis as well as other medical conditions (risk factors). All the contacts that an inhabitant has had throughout the period are assigned to the inhabitant, so that the intensity of the contacts at the different care levels can be identified (Fig. 1).

As at 31st December 2018, the database contained longitudinal data of 1.9 million inhabitants from four Spanish areas, of which 82,652 (4.4%) were aged < 5 years old. Only the two regions who use only ICD codes across all settings of care were included in this study, as ICPC-2 codes did not enable our three RSV case definitions to be used. This resulted in data from 51,292 children aged < 5 years old being included in this study.

Fig. 1
figure 1

Details of the database used in the study

Full size image

RSV case definition

Study population included child having an RSV-related event based on ICD-9-CM and ICD-10-ES codes used in the diagnosis, regardless if classified as a primary or secondary diagnosis, according to three distinct case definitions (Table 1): (a) RSV-specific; (b) RSV-specific and unspecified acute bronchiolitis (RSV-specific and Bronchiolitis), and; (c) RSV-specific and unspecified ALRI (RSV-specific and ALRI). Unless otherwise stated, results were presented for the broadest definition (RSV-specific and ALRI). These case definitions were based on findings from Cai et al., who reported a higher sensitivity for these broader definitions than RSV-specific ICD-10 codes, without sacrificing specificity [12].

Table 1 List of ICD-9 and ICD-10 diagnostic codes used to identify respiratory syncytial virus cases
Full size table

Population was stratified by age group [0–1] month, [1–2] months, [2–3] months, [3–6] months, [6–12] months, [12–24] months, [24–36] months and [36–60] months; [0–24] and [24–60] months; and [0–12] months. The number of RSV cases were divided by the population in the database for the same age group to compute a rate of cases per 1000 inhabitants.

RSV season

One season was analyzed as only two years (2017 and 2018) were available in the database. An ample definition of RSV season was considered, from September 2017 to June 2018, considering, as a reference, the period in which national surveillance systems for influenza (which also report RSV tests, when performed) are in place, plus a margin of approximately one month. This period improves the capacity to detect potential RSV cases, considering the variability in the RSV seasonality across years and countries [16,17,18]. Furthermore, laboratory-confirmed RSV cases had been reported in September in the previous season (2016/17) in a Spanish region [19].

Risk factors

Active diagnosis associated to the patients in the EMR during the analyzed period (chronical or acute pathologies) were used to identify children who had at least one medical condition regarded as a risk factor for RSV. The ICD-9-CM and ICD-10-ES diagnostic codes used to identify these risk factors (either as primary or related diagnostic) are detailed in the Additional file 1: Table S1. Risk factors such as heart disease, neuromuscular disorders, bronchopulmonary dysplasia, Down syndrome, immunodeficiency, congenital anomalies of respiratory system, congenital musculoskeletal anomalies, and cystic fibrosis were considered, based on expert advice. Patients were stratified by presence or absence of any of these risk factors/comorbidities. Premature birth, low weight or size at gestational age and exposure to tobacco were separately analyzed as potential risk factors as these are not underlying pathologies and may be less frequently inserted by medical coders.

Resource utilization estimation

An RSV episode was defined as the day of physician visit (in any setting) when the index diagnosis was made (index date), together with a related period of 14 days before and 14 days after the date of the diagnosis, as performed in a similar study for a respiratory infection [20]. During this period, the healthcare resource consumption of patients with RSV was considered to be due to RSV, with the following exceptions: (i) for outpatient consultations only visits to a set of specialties more likely related to RSV symptoms or complications were considered, based on expert advice; (ii) for hospitalizations, only episodes with RSV as the primary or secondary diagnosis were included. In this case, the 14 days period after the diagnosis was applied to the date of the discharge of the patient.

Two aspects are considered in the analysis of resource utilization. On one hand, how many RSV patients visited at least once each of the healthcare setting during their RSV episode. Then, for those who visited the service/healthcare setting at least once, mean number of visits to each healthcare setting per RSV patient were computed, namely visits to primary care (PC), outpatient specialized care (OP), emergency department (ED) and hospital (HO), as inpatient.

The prescription of pharmaceutical products likely to be prescribed for RSV was also analyzed but was not included in the results as it represented a cost lower than 1%, since only retail prescription products are captured by the database.

Cost estimation

The cost analysis was performed from the payer perspective and was based on resource utilization data combined with the unit cost of each resource. It comprised three steps and was stratified by age or by presence or absence of at least one risk factor.

Mean healthcare cost per case per setting

Firstly, mean healthcare costs per RSV patient who visited each healthcare setting were computed. At this stage, the previously computed mean number of visits to each healthcare setting of each medically attended RSV patient, during their RSV period, were multiplied by the unit cost of each of those healthcare visits, to compute the mean cost per patient who visited each healthcare setting.

The mean cost per RSV case per setting were computed for PC, OP, ED and HO. By mean costs per case per setting, we mean, for instance, the mean cost of HO per RSV case amongst RSV cases who were hospitalized during their RSV episode.

Mean healthcare cost per case

Then, these mean costs per case per setting were multiplied by the percentage of RSV cases in the database visiting each of the healthcare setting. As an example, the mean cost of HO per RSV case was obtained by multiplying the mean cost of HO amongst hospitalized RSV cases with the percentage of RSV cases who were hospitalized. The sum of the mean cost of PC, OP, ED and HO per RSV case results in the mean healthcare cost per RSV case.

Total healthcare cost of RSV cases in the database

The mean healthcare costs per case per setting were multiplied by the number of RSV cases visiting each healthcare setting in the database.

Unit costs of each resource

Unit cost per visit to each healthcare setting is not specific for RSV, except for hospitalization. Estimates of unit costs per type of healthcare visit were obtained from the eSalud Platform [21], considering official tariffs reported by autonomous communities, when available, and are detailed in Supporting Materials (Additional file 1: Table S2). For hospitalizations, the cost of each hospitalization observed in the database is individually estimated. The 3 M™ All Patient Refined Diagnosis Related Groups (APR DRGs) system (version 32) is used to calculate the degree of complexity for each hospitalization episode, considering variables related to the patient and episode. This is used to compute units of hospital production (UHP) for costing purposes [22, 23]. Estimated hospital mean cost per UHP is established for each hospital in the database considering the operating costs incurred by the hospital to carry out its activity to the production carried out by the hospital, measured through UHP. The average cost per UHP is updated annually through the IQVIA (former IASIST) Hospital TOP 20 Program.

Results

Studied population

Between September 2017 and June 2018, 3460 potential RSV cases were identified in the database in children aged < 5 years old, of which 257 (7.4%), 164 (4.7%), and 3,039 (87.8%) were coded with RSV-specific, unspecific bronchiolitis, and unspecific ALRI codes, respectively.

Medically attended cases per 1000 children were 25.2, 44.1 and 134.4 in children aged < 1 year, 3.6, 4.7 and 119.4 in children aged 2 years old, and 0.5, 0.6 and 35.3 in children aged between 2 and 5 years old, for RSV-specific, RSV-specific and Bronchiolitis and RSV-specific and ALRI codes, respectively. If only hospitalized cases were considered, these rates would be 25.0, 43.2 and 56.1 in children aged < 1 year, 3.6, 4.6 and 19.1 in children aged 2 years old, and 0.5, 0.5 and 3.6 in children aged between 2 and 5 years old, for RSV-specific, RSV-specific and Bronchiolitis and RSV-specific and ALRI cases, respectively. Table 2 reports the number of cases per 1000 inhabitants per age group, according to each RSV case definition, in total and for each visited healthcare setting only.

Table 2 Respiratory syncytial virus cases per 1000 children across settings of care, according to patients’ age (cases per 1000)
Full size table

Seasonality

Similar seasonality patterns were observed across the distinct RSV definitions, with November being the month with more reported cases, namely: 33.2% in RSV-specific, 25.6% in RSV-specific and Bronchiolitis and 17.2% in RSV-specific and ALRI. The months of November to March (inclusive) concentrated 82.6%, 74.9% and 61.8% of RSV-specific, RSV-specific and Bronchiolitis and RSV-specific and ALRI cases, respectively.

Demographics and clinical characteristics

The male to female ratio was 1.3, with 56.0% of RSV-specific and ALRI cases being observed in boys. Children aged < 1 year old accounted for 78.6%, 83.8% and 31.1% of RSV-specific, RSV-specific and Bronchiolitis and RSV-specific and ALRI cases, respectively. Amongst hospitalized cases, children aged < 1 year old accounted for 79.1%, 84.4% and 59.0% of RSV-specific, RSV-specific and Bronchiolitis and RSV-specific and ALRI cases, respectively. Children without any risk factor (i.e. otherwise healthy children) accounted for 87.9%, 87.9% and 93.1% of RSV-specific, RSV-specific and Bronchiolitis and RSV-specific and ALRI cases, respectively. Amongst the 6.9% of children presenting at least one risk factor for RSV in RSV-specific and ALRI cases, heart disease (2.9%) was the most frequently reported risk factor, followed by neuromuscular disorder (2.0%), congenital musculoskeletal anomalies (1.3%), congenital disorders of respiratory system (0.6%), Down syndrome (0.3%), immunodeficiency (0.2%), bronchopulmonary dysplasia (0.1%) and cystic fibrosis (0.1%). Prematurity was registered as a diagnosis in 1.2% of cases, low birth weight in 2.0% of cases and exposure to tobacco was not registered in any patient. Results for other case definitions, per age group, are detailed in Table 3.

Table 3 Percentage of respiratory syncytial virus patients, in total and by those visiting each healthcare setting, according to patients’ age or risk factors (% of cases)
Full size table

Resource utilization

RSV patients visiting each healthcare setting during their episode

Almost all RSV patients visited primary care (> 93%), regardless of the RSV definition and age group. The proportion of patients having an OP specialized care ranged from 10.1% in RSV-specific and ALRI to 14.3% in RSV-specific and Bronchiolitis. Most patients visited the ED, namely 99.6%, 98.8% and 54.3% of patients, in RSV-specific, RSV-specific and Bronchiolitis and RSV-specific and ALRI, respectively. The percentage of patients hospitalized for RSV was 98.4%, 97.4%, and 22.0% in RSV-specific, RSV-specific and Bronchiolitis and RSV-specific and ALRI, respectively.

On average, amongst RSV-specific and ALRI cases, 96.7% of children aged < 1 year old visited PC, 12.7% visited OP specialized care, 67.0% visited the ED and 41.7% were hospitalized for RSV.

Table 4 details the percentage of RSV patients who visited at least once each healthcare setting during their RSV episode, according to patients’ age and presence of risk factors, for each case definition.

Table 4 Percentage of respiratory syncytial virus patients visiting each healthcare setting during their episode, according to patients’ age or risk factors (% of cases visiting the service within cases observed in that age or risk factor group)
Full size table

Mean number of visits to each healthcare setting per visiting RSV patient

Amongst RSV-specific and ALRI cases with at least one visit to the healthcare setting, children aged < 1 year old had, on average, 9.3 visits to PC, 1.4 visits to OP specialized care, 2.3 visits to the ED and 1.2 hospitalizations for RSV. Mean visits per patient varied per age group but were relatively similar between patients who presented at least a risk factor compared to patients with no risk factor.

Table 5 presents the mean number of visits to each healthcare setting per RSV patient (amongst those who visited the healthcare setting at least once), according to patients’ age and presence of risk factors, for each case definition.

Table 5 Mean number of visits to each healthcare setting per respiratory syncytial virus patient visiting the healthcare setting at least once during their episode, according to patients’ age or risk factors (visits per patient*)
Full size table

Direct healthcare cost

Mean healthcare cost per case per setting

Amongst RSV-specific and ALRI cases in children aged < 1 year old, each child visiting PC generated a mean healthcare cost of PC visits of €486; mean cost of OP visits per RSV patient seeking OP care was estimated at €270; mean cost of ED visits per RSV patient visiting the ED was estimated at €408; and mean cost of hospitalization per hospitalized RSV patient was estimated at €2,335. These are mean costs per medically attended RSV patient and may include more than one visit per patient. These costs are detailed in Table 6 for each RSV definition and according to patients’ age and presence of risk factors.

Table 6 Mean direct healthcare costs of visits to each healthcare setting per respiratory syncytial virus patient who visited each healthcare setting and weighted total mean direct healthcare cost per respiratory syncytial virus patient, according to patients’ age or risk factors (€ per patient)
Full size table

Mean healthcare cost per case

Combining the mean healthcare costs per case per setting with the previously stated percentage of children aged < 1 year old visiting each healthcare setting, results in a mean healthcare cost per medically attended RSV-specific and ALRI case of €1753 in the first year of life (Fig. 2). This mean cost decreased to €896 in children aged two years old, and €683 between 2 and 5 years old. These costs are detailed in Table 6 for each RSV definition and according to patients’ age and presence of risk factors.

Fig. 2
figure 2

Mean healthcare cost per RSV-specific and ALRI case aged bellow one year old

Full size image

Total healthcare cost of medically attended RSV patients

In season 2017/18, the 3460 children aged < 5 years old who have been diagnosed with RSV-specific and ALRI codes in the two Spanish regions included in the study have cost €3.8 Million to the NHS, mainly driven by hospitalizations (45.8%, Table 7). Most of the healthcare costs were generated by children aged < 1 year old, who contributed to 78.7%, 84.0% and 50.0% of the healthcare costs of medically attended cases, for RSV-specific, RSV-specific and Bronchiolitis and RSV-specific and ALRI cases, respectively (Table 8). Most costs were generated by otherwise healthy children, regardless of age, who accounted for 86.1%, 84.5% and 86.9% of the direct healthcare costs of medically attended cases, for RSV-specific, RSV-specific and Bronchiolitis and RSV-specific and ALRI cases, respectively.

Table 7 Contribution of each healthcare setting to the total direct healthcare cost of medically attended respiratory syncytial virus patients, according to patients’ age or risk factors (% of total cost observed in that age or risk factor group)
Full size table
Table 8 Percentage of total direct healthcare cost of medically attended respiratory syncytial virus patients, generated by each group of patients’, according to their gender, age, and presence of risk factors (%)
Full size table

Table 7 details the contribution of the costs with each healthcare setting to the total direct healthcare cost of medically attended RSV patients (in percentage) for each RSV definition and according to patients’ age and presence of risk factors. Table 8 details the percentage of the total healthcare cost of medically attended RSV patients, generated by each group of patients’, according to their gender, age, and presence of risk factors, for each case definition.

Discussion

A high clinical and economic burden of medically attended ALRI cases potentially related to RSV occurs in children aged < 5 years old. To our knowledge, this is the first study reporting the burden of medically attended ALRI cases potentially related to RSV in Spanish children, considering distinct RSV definitions and healthcare settings. Using an EMR based database which includes all visits of the population from two Spanish regions to the NHS, for all healthcare settings, the study provides evidence on the burden of potential RSV disease in children < 5 years, beyond hospitalization. Such data is currently scarce in Europe as studies focus mostly on hospitalizations and it is vital for the definition of evidence-based preventive policies.

As expected, the need for medical care was particularly intense during the first year of life. These findings are consistent with results from other studies from western countries using similar methodologies for RSV-specific and unspecified acute bronchiolitis case [7, 24,25,26]. Incidence rates markedly decrease as age increases—as previously reported [13,14,15, 27]—being 20 times (RSV-Specific) and 28 times (RSV-Specific and Bronchiolitis) higher in children aged < 1 year old than in those aged between 1 and 5 years old.

Most cases were observed between November and March (61.8–82.6%, depending on the definition), as expected based on previous studies [16, 19]. The peak of cases was observed in November, as had also been reported for Galicia in the previous season [19].

Children who had a risk factor for RSV were 1.9 times more likely to be hospitalized for RSV-specific and ALRI (38.5% vs. 20.8% in those without a risk factor). No relevant differences were observed in the other case definitions as, regardless of presence of risk factors, almost all children were hospitalized for RSV (> 92%). The mean direct healthcare cost per medically attended potential RSV case also increased when a risk factor was present, which is coherent with published evidence that children with underlying medical conditions such as congenital heart disease, and chronic pulmonary and cardiovascular diseases, and prematurity, are more vulnerable to severe RSV infection [28,29,30]. However, even considering diagnosis received both in inpatient and outpatient setting to identify patients’ concurrent medical conditions, most identified RSV cases were observed in otherwise healthy children (87.9–93.1%, according to the RSV definition). This is consistent with previous national and international studies [6, 31]. A study on RSV bronchiolitis hospitalizations in Spain between 1997 and 2011 had identified 3.2% of cases with comorbidities, in those aged < 5 years old [29].

Three case definitions were used with most differences being observed between RSV-specific and ALRI and the other two (RSV-specific and RSV-specific and Bronchiolitis). Data appears to suggest that the latter definitions are mostly used for severe cases, as 99% of patients receiving these diagnoses visited the emergency services and over 97% have been hospitalized, versus 54% and 22% in RSV-specific and ALRI definition, respectively. This holds true even if only cases during the first year of life are considered. The proportion of cases generated by children aged < 1 year old also decreases as RSV definitions become “broader”, which might be a reflex of less frequent RSV testing and coding as age increases. In 2009, a multicenter Spanish study including 5,647 children < 2 years old with a first acute bronchiolitis episode – of which 51.2% proceeding from the emergency department, 28.9% from hospitalizations, 18.3% from primary care and 1.6% from ICU - has reported that RSV diagnosis tests were performed in only 37.4% of acute bronchiolitis medically attended cases, of which 63.5% were RSV-positive and found that younger age was associated with increased likelihood of being tested for RSV.[32] An international study has also reported decreased testing among children aged above six months [27]. Other authors have also reported that RSV-positive cases are more frequently diagnosed as bronchiolitis in patients aged < 1 year old while in children aged between 2 and 5 years old, pneumonia was more frequent [7]. Overall, evidence suggests a potential age-associated bias in the diagnosis of RSV in children admitted for RSV-associated respiratory disease, supported also by the uncommon diagnosis of RSV-associated pneumonia [14, 33, 34].

The present study highlighted the magnitude of potentially underestimated RSV cases, especially using RSV-specific codes. Cases per 1000 were 1.6 and 13.5 times higher using the RSV-specific and Bronchiolitis and the RSV-specific and ALRI definition, respectively, than using RSV-specific codes alone. In hospitalized cases per 1000 children the increase was the same for RSV-specific and Bronchiolitis but only 1.9 for RSV-specific and ALRI. Results appear to support previous findings that combining RSV-specific with unspecified ALRI ICD diagnosis may indeed help to better understand the burden of RSV, particularly if testing is not systematically performed in a specific healthcare setting or region [1, 11, 12]. In the U.S., Hall et al. had also found a greater RSV diagnosis capacity at the hospitals, reporting that only 3% of outpatients with RSV infection received the diagnosis of RSV-associated illness, as compared with 45% of inpatients [7].

We reported rates of 8.0 hospitalized children per 1,000 children aged < 5 years old using RSV-specific and Bronchiolitis and 21.6 in those aged < 2 years old, which are similar to those reported by Gil-Prieto et al. for Spain, namely of 10.7 and 24.1 per 1,000 children aged bellow 5 and 2 years old, respectively, during 1997–2011 [29]. In Valencia, a population study on 198,223 children born between 2009 and 2012, has reported an incidence rate of bronchiolitis (all causes) of 164 cases per 1000 children aged < 2 years old, which was 87% lower if only hospitalized cases were considered (21 per 1000) [13]. Amongst those hospitalized, 57.6% had either an RSV ICD-9 diagnosis or had a positive RSV test result [13]. Assuming that the same rate of RSV-cases coded as bronchiolitis could be observed in the outpatient setting this would result in an incidence rate of approximately 94 RSV cases per 1000 children, which is closer to the one obtained by our RSV-specific and ALRI definition (126 per 1000) than in RSV-Specific and Bronchiolitis (22 per 1000). This difference might reflect regional variations in testing and coding practices, but, in both cases, reflects a high burden of acute respiratory infections in Spanish children that needs to be better understood and addressed. Further studies combining health administrative data and RSV laboratory data for Spain to assess the validity of each diagnosis code in Spain would be of interest, although regional variation must be accounted for.

An important limitation of this study is that it does not enable to quantify the proportion of the reported unspecified ALRI cases that have been caused by RSV, and not by other infectious agents, which may unduly inflate the estimates calculated under the definition RSV-specific and ALRI. While several studies name RSV as the most common pathogen identified in young children with ALRI (mainly pneumonia and bronchiolitis) [1, 35, 36], there are other infectious agents that can cause severe ALRI— such as pneumonia—including viruses, bacteria and fungi [35, 37] In children, bacterial pneumonia is most often caused by Streptococcus pneumoniae (pneumococcus) or by Haemophilus influenzae type b (Hib) while RSV is the most common viral cause of pneumonia [35, 37], with a role that is expected to increase as the use of vaccines against the most common types of bacterial pneumonia grows [38,39,40], as well as the capacity to detect virus through molecular diagnostic, as differentiating between viral and bacterial pneumonias radiographically is difficult [35]. A systematic review and meta-analysis performed by Shi et al. (2015) found evidence supporting that RSV, influenza (IFV), parainfluenza (PIV), human metapneumovirus (HMPV), and rhinovirus (RV) are important causes of ALRI in young children, estimating the percentage of (severe) ALRI which could be attributed to each virus to be 90%, 80%, 70%, 73% and 30%, respectively [41].

However, few studies on pneumonia etiology were conducted in high-income countries [40]. A recent prospective case–control study performed in West Australia has estimated the contribution of respiratory viruses and bacteria to pneumonia in people aged < 18 years. The study reported that RSV had the highest contribution amongst detectable respiratory viruses responsible for the analyzed pneumonias requiring hospitalization and concluded that RSV and HMPV are probable pneumonia-causing pathogens in children with pneumonia [40]. It is thus reasonable to expect that, while this broader RSV-specific and ALRI definition may have the benefit of potentially capturing more cases of RSV caused ALRI, it may also have the pitfall of potentially including non-RSV caused ALRI [11, 12].

In either case, findings from the BARI study support that RSV is a major driver of demand of healthcare resources at all levels of care in children, resulting in important costs to the NHS. Hospitalization rates were higher in children bellow 2 years old. In our study, children aged bellow 2 years old accounted for 78.8–94.9% of total direct healthcare costs of medically attended RSV patients aged bellow 5 years old, and 84.6–94.7% of hospitalization costs, which is consistent with previous findings for Spain [29]. An important part of the cost was driven by children aged bellow 1 year old, who accounted for 50.0–84.0% of total direct healthcare costs of medically attended RSV patients aged bellow 5 years old, and 60.7–83.9% of hospitalization costs. Otherwise healthy children generated most of the NHS costs (84.5–86.9%, according to the RSV definition). Mean direct healthcare cost per patient with RSV-specific diagnosis was higher, given the greater proportion of patients visiting the emergency department or being hospitalized, namely €3,357, €3,345, and €3,362 in patients aged < 5, <2 and < 1 year old, respectively.

Still, RSV burden is expected to be even higher if other factors are considered. A high frequency of primary care visits during the 28 days around the RSV diagnosis was found in our study, suggesting not only a burden for the healthcare system but potentially relevant productivity losses from the children’s parents, which were not quantified in our study. Importantly, children having severe RSV infection are more likely to develop respiratory complications such as wheezing and asthma, generating a long term burden for those infected [1, 5, 10]. A study found that premature infants infected by RSV had almost twice the number of primary care visits than controls during the two years following the RSV infection.[42] An important limitation of our study was that this long-lasting burden of the RSV-infection was not studied.

The major limitations of the present study are that it is based on a population sample and that it relies on data from an EMR database without information of whether RSV laboratory testing was performed. Data is subject to coding errors or missing information. Due to the low precision of RSV codification in primary care the studied population may be biased towards more severe RSV cases. The method used to estimate resource utilization during the RSV period may overestimate the number of visits due to RSV, as some could have been performed, regardless of RSV diagnosis. As previously mentioned, the study does not consider healthcare resources consumed in a private healthcare setting, nor indirect costs related to productivity losses or long-term burden. Importantly, the database is not aimed to be nationally representative as population from only two regions was used. Furthermore, this study was performed only during one RSV season, which can limit comparisons with results from other studies as RSV is a seasonal disease that commonly displays annual or biennial seasonality.

Conclusions

RSV is a major driver of demand for medical care by Spanish children. The burden of RSV is particularly high in children under 1 year of age. Most cases and direct healthcare costs were observed in otherwise healthy children born at term. Analyzing only hospitalizations and RSV-specific diagnosis is expected to substantially underestimate the burden of the disease to the NHS. These findings highlight the need to improve RSV testing and surveillance, and to adopt preventive solutions that enable protection of all infants, particularly during the first year of life.

Availability of data and materials

The data that support the findings of this study are available from IQVIA, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of IQVIA. Those wishing to request the data from this study should contact the author Mafalda Carmo.

References

  1. Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, Simões EA, Carbonell-Estrany X. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis therapy. 2016;5(3):271–98.

    Article  Google Scholar 

  2. Hodgson D, Pebody R, Panovska-Griffiths J, Baguelin M, Atkins KE. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis. BMC Med. 2020;18(1):348.

    Article  Google Scholar 

  3. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simões EAF, Campbell H, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. The Lancet. 2022;399(10340):2047–64.

    Article  Google Scholar 

  4. Stein RT, Bont LJ, Zar H, Polack FP, Park C, Claxton A, Borok G, Butylkova Y, Wegzyn C. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol. 2017;52(4):556–69.

    Article  Google Scholar 

  5. Díez-Domingo J, Pérez-Yarza EG, Melero JA, Sánchez-Luna M, Aguilar MD, Blasco AJ, Alfaro N, Lázaro P. Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infect Dis. 2014;14:544–4.

    Article  Google Scholar 

  6. Murray J, Bottle A, Sharland M, Modi N, Aylin P, Majeed A, Saxena S. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS ONE. 2014;9(2):e89186.

    Article  Google Scholar 

  7. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98.

    Article  CAS  Google Scholar 

  8. Viguria N, Martínez-Baz I, Moreno-Galarraga L, Sierrasesúmaga L, Salcedo B, Castilla J. Respiratory syncytial virus hospitalization in children in northern Spain. PLoS ONE. 2018;13(11):e0206474.

    Article  Google Scholar 

  9. Mammas IN, Drysdale SB, Rath B, Theodoridou M, Papaioannou G, Papatheodoropoulou A, Koutsounaki E, Koutsaftiki C, Kozanidou E, Achtsidis V, et al. Update on current views and advances on RSV infection (Review). Int J Mol Med. 2020;46(2):509–20.

    Article  CAS  Google Scholar 

  10. Prasad N, Newbern EC, Trenholme AA, Wood T, Thompson MG, Aminisani N, Huang QS, Grant CC. Respiratory syncytial virus hospitalisations among young children: a data linkage study. Epidemiol Infect. 2019;147:e246.

    Article  Google Scholar 

  11. Hamilton MA, Calzavara A, Emerson SD, Djebli M, Sundaram ME, Chan AK, Kustra R, Baral SD, Mishra S, Kwong JC. Validating International Classification of Disease 10th Revision algorithms for identifying influenza and respiratory syncytial virus hospitalizations. PLoS ONE. 2021;16(1):e0244746.

    Article  CAS  Google Scholar 

  12. Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, Buda S. Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14(6):630–7.

    Article  CAS  Google Scholar 

  13. Muñoz-Quiles C, López-Lacort M, Úbeda-Sansano I, Alemán-Sánchez S, Pérez-Vilar S, Puig-Barberà J, Díez-Domingo J. Population-based Analysis of Bronchiolitis Epidemiology in Valencia, Spain. Pediatr Infect Dis J. 2016;35(3):275–80.

    Article  Google Scholar 

  14. Heppe-Montero M, Walter S, Hernández-Barrera V, Gil-Prieto R, Gil-de-Miguel Á. Burden of respiratory syncytial virus-associated lower respiratory infections in children in Spain from 2012 to 2018. BMC Infect Dis. 2022;22(1):315.

    Article  Google Scholar 

  15. Heppe Montero M, Gil-Prieto R, Walter S, Aleixandre Blanquer F, Gil De Miguel Á. Burden of severe bronchiolitis in children up to 2 years of age in Spain from 2012 to 2017. Hum vaccines immunotherapeutics. 2022;18(1):1883379.

    Article  Google Scholar 

  16. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodríguez-Tenreiro C, Sly P, Ramilo O, Mejías A, Baraldi E, Papadopoulos NG, Nair H, et al. Respiratory syncytial virus seasonality: a global overview. J Infect Dis. 2018;217(9):1356–64.

    Article  Google Scholar 

  17. Bloom-Feshbach K, Alonso WJ, Charu V, Tamerius J, Simonsen L, Miller MA, Viboud C. Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. PLoS ONE. 2013;8(2):e54445.

    Article  CAS  Google Scholar 

  18. Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on prevention strategies. Hum Vacc Immunothera. 2018;14(1):234–44.

    Article  Google Scholar 

  19. Servia-Dopazo M, Purriños-Hermida MJ, Pérez S, García J, Malvar-Pintos A. Utilidad de la vigilancia microbiológica del virus respiratorio sincitial en Galicia (España): 2008–2017. Gac Sanit. 2020;34:474–9.

    Article  Google Scholar 

  20. Ehlken B, Anastassopoulou A, Hain J, Schröder C, Wahle K. Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany—results of a database analysis from May 2010 to April 2012. BMC Public Health. 2015;15(1):578.

    Article  Google Scholar 

  21. eSalud-Información económica del sector sanitario http://oblikue.com/bddcostes/.

  22. García-Eroles L, Illa C, Arias A, Casas M. Los Top 20 2000: objetivos, ventajas y limitaciones del método. Rev Calidad Asistencial. 2001;16(2):107–16.

    Article  Google Scholar 

  23. Sánchez-Martínez F, Abellán-Perpiñán JM, Martínez-Pérez JE, Puig-Junoy J. Cost accounting and public reimbursement schemes in Spanish hospitals. Health Care Manag Sci. 2006;9(3):225–32.

    Article  Google Scholar 

  24. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137(6):865–70.

    Article  CAS  Google Scholar 

  25. García CG, Bhore R, Soriano-Fallas A, Trost M, Chason R, Ramilo O, Mejias A. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics. 2010;126(6):e1453–60.

    Article  Google Scholar 

  26. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA, Szilagyi PG, Griffin MR, Williams JV, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341–8.

    Article  Google Scholar 

  27. Arriola CS, Kim L, Langley G, Anderson EJ, Openo K, Martin AM, Lynfield R, Bye E, Como-Sabetti K, Reingold A, et al. Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged < 2 years in the United States, 2014–15. J Pediatr Infect Dis Soc. 2020;9(5):587–95.

    Article  CAS  Google Scholar 

  28. Aujard Y, Fauroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir Med. 2002;96(Suppl B):9–14.

    Article  Google Scholar 

  29. Gil-Prieto R, Gonzalez-Escalada A, Marín-García P, Gallardo-Pino C, Gil-de-Miguel A. Respiratory syncytial virus bronchiolitis in children up to 5 years of age in Spain: epidemiology and comorbidities: an observational study. Medicine. 2015;94(21):e831.

    Article  Google Scholar 

  30. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet (London England). 2017;390(10098):946–58.

    Article  Google Scholar 

  31. Mendes-da-Silva A, Gonçalves Pinho M, Freitas A, Azevedo I. Trends in hospitalization for acute bronchiolitis in Portugal: 2000–2015. Pulmonology. 2018; 25.

  32. González de Dios J, Ochoa Sangrador C. Estudio de variabilidad en el abordaje de la bronquiolitis aguda en España en relación con la edad de los pacientes. Anal Pediatr. 2010; 72(1):4–18.

  33. JUVéN T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen M, Eskola J, Saikku P, Ruuskanen O. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19(4):293–8.

    Article  Google Scholar 

  34. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. The Lancet. 2011;377(9773):1264–75.

    Article  Google Scholar 

  35. Simoes EA, Cherian T, Chow J, Shahid-Salles SA, Laxminarayan R, John TJ. Acute respiratory infections in children. Disease Control Priorities in Developing Countries 2nd edition 2006.

  36. Simoes EA. Respiratory syncytial virus infection. The Lancet. 1999;354(9181):847–52.

    Article  CAS  Google Scholar 

  37. Pneumonia. Key facts. http://www.who.int/news-room/fact-sheets/detail/pneumonia.

  38. Fathima P, Blyth CC, Lehmann D, Lim FJ, Abdalla T, De Klerk N, Moore HC. The impact of pneumococcal vaccination on bacterial and viral pneumonia in Western Australian children: record linkage cohort study of 469589 births, 1996–2012. Clin Infect Dis. 2018;66(7):1075–85.

    Article  Google Scholar 

  39. Griffin MR, Mitchel E, Moore MR, Whitney CG, Grijalva CG. Declines in pneumonia hospitalizations of children aged < 2 years associated with the use of pneumococcal conjugate vaccines—Tennessee, 1998–2012. Morbid Mortal Wkly Rep. 2014; 63(44):995.

  40. Bhuiyan MU, Snelling TL, West R, Lang J, Rahman T, Granland C, de Gier C, Borland ML, Thornton RB, Kirkham L-AS, et al. The contribution of viruses and bacteria to community-acquired pneumonia in vaccinated children: a case– control study. Thorax. 2019;74(3):261–9.

    Article  Google Scholar 

  41. Shi T, McLean K, Campbell H, Nair H. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: a systematic review and meta-analysis. J Global Health. 2015;5(1):010408.

    Article  Google Scholar 

  42. Shefali-Patel D, Paris MA, Watson F, Peacock JL, Campbell M, Greenough A. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012;171(7):1055–61.

    Article  Google Scholar 

Download references

Acknowledgements

None.

Funding

The BARI study was funded by Sanofi.

Author information

Authors and Affiliations

  1. Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario and Universidad de Santiago de Compostela, Galicia, Spain

    F. Martinón-Torres

  2. Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), Rúa da Choupana, s/n, Santiago de Compostela, Galicia, 15706, A Coruña, Spain

    F. Martinón-Torres

  3. CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

    F. Martinón-Torres

  4. IQVIA, Barcelona, Spain

    M. Carmo

  5. Sanofi, Madrid, Spain

    L. Platero

  6. Sanofi, Barcelona, Spain

    G. Drago & J. L. López-Belmonte

  7. Sanofi, Lyon, France

    M. Bangert

  8. Vaccine Research Department, FISABIO, Valencia, Spain

    J. Díez-Domingo

  9. Pediatrics Service, Nazaret Health Center, Valencia, Spain

    M. Garcés-Sánchez

Authors
  1. F. Martinón-Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Carmo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Platero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Drago
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. L. López-Belmonte
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Bangert
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Díez-Domingo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Garcés-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors have contributed to the protocol revision, critical analysis, and discussion of the study results, and for redacting and revising the manuscript. MC has conducted the technical analysis of the BARI study. All authors read and approved the final manuscript.

Corresponding author

Correspondence to F. Martinón-Torres.

Ethics declarations

Ethics approval and consent to participate

The study was conducted following the ethical principles of the Declaration of Helsinki and the local regulation, including privacy laws. The protocol of the BARI study was validated by a panel of clinical experts, classified by the Agency of Medicines and Medical Devices (AEMPS) as an observational study and approved by the Ethics Committee of Hospital Clinic de Barcelona (HCB/2020/1132). Informed consent to participate was waived by the same ethics committee that approved the study (Ethics Committee of Hospital Clinic de Barcelona).

Consent for publication

None.

Competing interests

Platero L, Drago G, López-Belmonte JL and Bangert M are Sanofi employees and may hold shares and/or stock options in the company. Carmo M is an IQVIA employee. Martinón Torres F and Díez-Domingo J have received fees from Sanofi. F.M-T. received honoraria from GSK group of companies, Pfizer Inc, Sanofi Pasteur, MSD, Seqirus, and Janssen for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. FM-T has also acted as principal investigator in randomized controlled trials of the above-mentioned companies as well as Ablynx, Gilead, Regeneron, Roche, Abbott, Novavax, and MedImmune, with honoraria paid to his institution. F.M-T has received support for the present work from the Instituto de Salud Carlos III (Proyecto de Investigación en Salud, Acción Estratégica en Salud): Fondo de Investigación Sanitaria (FIS; PI070069/PI1000540/PI1601569/PI1901090) del plan nacional de I + D + I and ‘fondos FEDER’ and Proyectos GaIN Rescata-Covid_IN845D 2020/23 (GAIN, Xunta de Galicia). Garcés-Sánchez M received honoraria from GSK, Pfizer Inc, Sanofi and MSD for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: 

Table S1. List of analyzed risk factors andICD9/10 codes used. Table S2. Unit costs considered for each healthcare visit.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Martinón-Torres, F., Carmo, M., Platero, L. et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis 22, 759 (2022). https://doi.org/10.1186/s12879-022-07745-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12879-022-07745-0

Keywords

BMC Infectious Diseases

ISSN: 1471-2334

Contact us